Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Objective The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. Design In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn'...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2012-12, Vol.61 (12), p.1693-1700
Hauptverfasser: Hueber, Wolfgang, Sands, Bruce E, Lewitzky, Steve, Vandemeulebroecke, Marc, Reinisch, Walter, Higgins, Peter D R, Wehkamp, Jan, Feagan, Brian G, Yao, Michael D, Karczewski, Marek, Karczewski, Jacek, Pezous, Nicole, Bek, Stephan, Bruin, Gerard, Mellgard, Bjoern, Berger, Claudia, Londei, Marco, Bertolino, Arthur P, Tougas, Gervais, Travis, Simon P L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!